Cancer Discov. 2017 Oct;7(10):OF6. doi: 10.1158/2159-8290.CD-NB2017-114. Epub 2017 Aug 14.
A new study shows that chimeric antigen receptor T cells produce objective responses in 71% of patients with chronic lymphocytic leukemia whose disease progressed despite receiving ibrutinib or who are unable to tolerate the drug. Cancer cells were undetectable in the bone marrow in 81% of tested patients, and 64% of tested patients showed complete lymph node responses. Most patients experienced adverse effects, however.
一项新研究表明，嵌合抗原受体 T 细胞在 71%的慢性淋巴细胞白血病患者中产生了客观反应，这些患者尽管接受了伊布替尼治疗或无法耐受该药物，但疾病仍在进展。在接受检测的患者中，81%的患者骨髓中无法检测到癌细胞，64%的患者出现完全淋巴结反应。然而，大多数患者出现了不良反应。
